Sekar Kathiresan, MD
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease

N Engl J Med November 13, 2016. DOI: 10.1056/NEJMoa1605086

Both genetic and lifestyle factors contribute to individual-level risk of coronary artery disease. The extent to which increased genetic risk can be offset by a healthy lifestyle is unknown. Across four studies involving 55,685 participants, genetic and lifestyle factors were independently associated with susceptibility to coronary artery disease. Among par- ticipants at high genetic risk, a favorable lifestyle was associated with a nearly 50% lower relative risk of coronary artery disease than was an unfavorable lifestyle. (Funded by the National Institutes of Health and others.)

 Genetic-Risk-Adherence-to-a-Healthy-Lifestyle-and-Coronary-Disease.pdf
W. Taylor Kimberly, MD, PhD
Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial

Lancet Neurol. 2016 Oct;15(11):1160-9. doi: 10.1016/S1474-4422(16)30196-X. Epub 2016 Aug 23.

Preclinical models of stroke have shown that intravenous glyburide reduces brain swelling and improves survival. We assessed whether intravenous glyburide (RP-1127; glibenclamide) would safely reduce brain swelling, decrease the need for decompressive craniectomy, and improve clinical outcomes in patients presenting with a large hemispheric infarction. Intravenous glyburide was well tolerated in patients with large hemispheric stroke at risk for cerebral oedema. There was no difference in the composite primary outcome. Further study is warranted to assess the potential clinical benefit of a reduction in swelling by intravenous glyburide.

 Safety-and-efficacy-of-intravenous-glyburide-on-brain-swelling-after-large-hemispheric-infarction-GAMES-RP-a-randomised-double-blind-placebo-controlle.pdf

Susan A. Slaugenhaupt

My research focuses on two neurological disorders, familial dysautonomia (FD) and mucolipidosis type IV (MLIV), as well as the common cardiac disorder mitral valve prolapse (MVP).   Our work is focused […]

Read More…

James Walker

Dr. Jim Walker received his Ph.D. in Biochemistry from the University of Cambridge and carried out post-doctoral training at Massachusetts General Hospital. His research focuses on understanding the genetics and […]

Read More…

Michael Talkowski

Dr. Talkowski received a Ph.D. in human genetics and performed his postdoctoral training in neurodevelopmental genomics. The Talkowski laboratory is interested in understanding the consequence of genomic variation on human […]

Read More…

David Sweetser

Dr. Sweetser received his B.S. in Biological Science with Honors from Stanford University in 1982, his M.D./Ph.D. at Washington University in St. Louis, followed by a  Pediatric Residency at St. […]

Read More…

Jordan W. Smoller

Dr. Smoller is Professor of Psychiatry at HMS, and Professor in Epidemiology at the Harvard T.H. Chan School of Public Health. At MGH, he is the Trustees Endowed Chair in Psychiatric […]

Read More…

Brian Skotko

A Board-certified medical geneticist and Co-Director of the Down Syndrome Program at Massachusetts General Hospital, Dr. Skotko has dedicated his professional energies toward children with cognitive and development disabilities. In 2001 […]

Read More…

Richa Saxena

Richa Saxena, a human geneticist, uses genetics to understand the biological basis of people’s daily behavioral rhythms and sleep patterns, and to illuminate meaningful links of sleep and circadian rhythms […]

Read More…

Jonathan Rosand

Jonathan is a clinician-scientist with expertise in genetics who has devoted his professional life to caring for patients with the most devastating brain injuries and to reducing the impact of […]

Read More…